Association of human papillomavirus related squamous cell carcinomas of the oropharynx and cervix

Gazzaz, Malak Jamal; Jeffery, Caroline C.; O’Connell, Daniel A.; Harris, Jeffrey R.; Seikaly, Hadi; Biron, Vincent L.

doi:10.1016/j.pvr.2019.100188

Cited by 6 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[17][18][19][20][21][22] Authors have noted a temporal disease relationship, with cervical disease preceding OPSCC. 14,15,17,19 In contrast, we found a similar proportion with disease before and/or after HPV-positive OPSCC, likely due to our prospective contact, which identified additional care at outside institutions.…”

Section: Discussionmentioning

confidence: 63%

Human Papillomavirus–Associated Anogenital Pathology in Females With HPV‐Positive Oropharyngeal Squamous Cell Carcinoma

Larish

Yin

Glaser

et al. 2020

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

We sought to determine the incidence and location of human papillomavirus (HPV)–associated anogenital disease in women with HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) via a retrospective cohort study with prospective contact to update history at Mayo Clinic in Rochester, Minnesota. Females undergoing treatment for nonmetastatic HPV-positive OPSCC from 2011 to 2019 were identified. Clinical history and outcomes were abstracted from medical records. Patients without documented anogenital history were contacted, consented, and administered a survey, and external records were requested and reviewed. Seventeen of 46 patients (37.0%) had a history of anogenital HPV-associated disease, and 16 of 17 (94.1%) required procedures to diagnose or treat HPV lesions. The cervix was the most common site (16/17, 94.1%). Procedures included colposcopy (n = 6), cervical excision (n = 3), cryotherapy (n = 4), and hysterectomy (n = 3). One case of fatal cervical carcinoma was noted, diagnosed 1 year following OPSCC. Three of 17 (17.6%) had HPV-related vulvovaginal disease, and 1 of 17 had anal disease. Patients with a history of HPV-positive OPSCC may be at elevated risk for HPV-associated anogenital disease.

show abstract

Section: Discussionmentioning

confidence: 63%

Human Papillomavirus–Associated Anogenital Pathology in Females With HPV‐Positive Oropharyngeal Squamous Cell Carcinoma

Larish

Yin

Glaser

et al. 2020

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

show abstract

“…Most studies (n=80, 70%) ( 4 , 15 – 93 ) evaluated oral and cervical sites with synchronous HPV testing; the remaining studies were divided between asynchronous evaluations (n=12, 11%) ( 94 – 105 ) and cancer diagnoses only (n=22, 19%) ( 106 – 127 ). Combining synchronous ( 4 , 15 – 93 ) and asynchronous ( 94 – 105 ) study data, the overall estimate of oral and cervical dual-site HPV infections was 16% and the overall estimate of oral-cervical HPV type concordance among dually-infected women was 41% ( Table 1 ).…”

Section: Resultsmentioning

confidence: 99%

“…Combining synchronous ( 4 , 15 – 93 ) and asynchronous ( 94 – 105 ) study data, the overall estimate of oral and cervical dual-site HPV infections was 16% and the overall estimate of oral-cervical HPV type concordance among dually-infected women was 41% ( Table 1 ). Among cancer diagnoses only studies ( 106 – 127 ), the incidence of a secondary cervical cancer diagnosis ranged from as few as 4.5/10,000 to as many as 192.5/10,000 women; the incidence of a secondary oral HPV-related cancer ranged from 1.0 to 45.8 per 10,000 women.…”

Section: Resultsmentioning

confidence: 99%

“…Twenty-two retrospective studies focused on the diagnosis of a secondary cervical or oral cancer after a primary cancer diagnosis of oral or cervical cancer ( 106 – 127 ) ( Table 2C ). Although we specifically included studies focused on HPV-related oral cancers, the sites of oral cancers varied across studies (e.g., some studies included oropharynx, oral cavity and pharynx, some only included oropharyngeal, and some vaguely defined HPV-related head and neck sites).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Low Rates of Dual-Site and Concordant Oral-Cervical Human Papillomavirus Infections and Cancers: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

ObjectiveThe oral-cervical human papillomavirus (HPV) infection/cancer relationship is not well established. Oral-cervical HPV studies were reviewed to assess dual-site occurrence, HPV type concordance, and study quality/deficiencies.MethodsPubMed, EMBASE, Ovid Medline, and Web of Science were searched between 1/1/1990 and 8/10/2021 for studies investigating HPV infections/cancers and type concordance between the oral cavity/oropharynx and cervix. Dual-site and concordant HPV infection rates were summarized as percentages; cancer diagnoses studies were summarized using standardized incidence ratios (SIR). The Quality Assessment Tool for Quantitative Studies (QATQS) evaluated study methodology.ResultsOne hundred fourteen papers were identified. Most were cross-sectional (n=79, 69%), involved synchronous dual-site HPV testing (n=80, 70%), did not report HPV type concordance (n=62, 54%), and achieved moderate methodological QATQS ratings (n=81, 71%). The overall dual-site infection rate averaged 16%; the HPV type concordance rate averaged 41%, among those dually-infected women. Most HPV-related cancer diagnoses studies reported increased secondary cancer risk, with SIRs generally ranging from 1.4 to 29.4 for secondary cervical cancer after primary oral cancer and from 1.4 to 6.3 for secondary oral cancer after primary cervical cancer.Conclusion/ImpactOral-cervical HPV infections/cancers remain understudied. Future research should use stronger methodologies and HPV concordance analyses to better understand oral-cervical HPV epidemiology.

show abstract

“…Interestingly, female patients with p16-positive OPSCC showed a higher incidence of HPV+ cervical cancer [127]. Even though the incidence of HPV+ OPSCC is lower in females, the immune response to HPV is important for cancer prevention, and those who are not able to mount an adequate immune response may be more susceptible to future HPV-associated cancers.…”

Section: Race Sex and Disparity In Hpv+ And Hpv− Hnsccsmentioning

confidence: 99%

The Key Differences between Human Papillomavirus-Positive and -Negative Head and Neck Cancers: Biological and Clinical Implications

Powell

Spanos

et al. 2021

Cancers

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is a unique malignancy associated with two distinct risk factors: exposure to typical carcinogens and infection of human papillomavirus (HPV). HPV encodes the potent oncoproteins E6 and E7, which bypass many important oncogenic processes and result in cancer development. In contrast, HPV-negative HNSCC is developed through multiple mutations in diverse oncogenic driver genes. While the risk factors associated with HPV-positive and HPV-negative HNSCCs are discrete, HNSCC patients still show highly complex molecular signatures, immune infiltrations, and treatment responses even within the same anatomical subtypes. Here, we summarize the current understanding of biological mechanisms, treatment approaches, and clinical outcomes in comparison between HPV-positive and -negative HNSCCs.

show abstract

Association of human papillomavirus related squamous cell carcinomas of the oropharynx and cervix

Cited by 6 publications

References 30 publications

Human Papillomavirus–Associated Anogenital Pathology in Females With HPV‐Positive Oropharyngeal Squamous Cell Carcinoma

Human Papillomavirus–Associated Anogenital Pathology in Females With HPV‐Positive Oropharyngeal Squamous Cell Carcinoma

Low Rates of Dual-Site and Concordant Oral-Cervical Human Papillomavirus Infections and Cancers: A Systematic Review

The Key Differences between Human Papillomavirus-Positive and -Negative Head and Neck Cancers: Biological and Clinical Implications

Contact Info

Product

Resources

About